Neuregulin-1 administration protocols sufficient for stimulating cardiac regeneration in young mice do not induce somatic, organ, or neoplastic growth

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Ganapathy, Balakrishnan ^a,b   Nandhagopal, Nikitha ^b,c   Polizzotti, Brian D ^a,d   Bennett, David ^e,h   Asan, Alparslan ^b,f   Wu, Yijen ^b,f   Kühn, Bernhard ^a,b,d,g  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c University of Pittsburgh   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

^h PAREXEL INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEU DIFFERENTIATION FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT NEUREGULIN 1; S6 KINASE; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIAC REGENERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN GROWTH; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE REGENERATION; WESTERN BLOTTING; AGING; ANIMAL; BLOOD; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEART; HUMAN; KIDNEY; METABOLISM; MORPHOGENESIS; NEOPLASM; NEWBORN; ORGAN SIZE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REGENERATION;

AGING; ANIMALS; ANIMALS, NEWBORN; ERBB RECEPTORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HEART; HUMANS; KIDNEY; MICE; MORPHOGENESIS; NEOPLASMS; NEUREGULIN-1; ORGAN SIZE; PHOSPHORYLATION; RECOMBINANT PROTEINS; REGENERATION; RIBOSOMAL PROTEIN S6 KINASES;

EID: 84970028928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155456     Document Type: Article

References (42)

1. Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, et al. Cardiovascular Drug Development: Is it Dead or Just Hibernating? J Am Coll Cardiol. 2015; 65(15):1567-82. doi:10.1016/j.jacc.2015.03. 016 PMID: 25881939.
2. Burns KM, Byrne BJ, Gelb BD, Kuhn B, Leinwand LA, Mital S, et al. New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute Working Group. Circulation. 2014; 130(1):79-86. Epub 2014/07/02. doi:10.1161/CIRCULATIONAHA.113. 007980 PMID: 24982119.
3. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA: the journal of the American Medical Association. 2007; 298(10):1171-9. Epub 2007/09/13. doi:10.1001/jama.298.10.1171 PMID: 17848651.
4. Hsu DT, Zak V, Mahony L, Sleeper LA, Atz AM, Levine JC, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation. 2010; 122(4):333-40. Epub2010/07/14. doi:10.1161/CIRCULATIONAHA.109.927988 PMID: 20625111.
5. Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell. 2009; 138(2):257-70. PMID: 19632177. doi:10.1016/j.cell.2009.04.060
6. Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, et al. A phase II, randomized, double-blind, multi-center, based on standart therapy, placebo-controlled study of th efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010; 55(18):1907-14. doi: 10.1016/j.jacc.2009.12.044 PMID: 20430261
7. Liu X, Gu X, Li Z, Li X, Li H, Chang J, et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006; 48(7):1438-47. PMID: 17010808.
8. Cohen JE, Purcell BP, MacArthur JW Jr., Mu A, Shudo Y, Patel JB, et al. Abioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy. Circ Heart Fail. 2014; 7(4):619-26. doi:10.1161/CIRCHEARTFAILURE.113.001273 PMID: 24902740; PubMed Central PMCID: PMC4157671.
9. Formiga FR, Pelacho B, Garbayo E, Imbuluzqueta I, Diaz-Herraez P, Abizanda G, et al. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration. Journal of controlled release: official journal of the Controlled Release Society. 2014; 173:132-9. doi:10.1016/j.jconrel.2013.10.034 PMID: 24200746.
10. Galindo CL, Kasasbeh E, Murphy A, Ryzhov S, Lenihan S, Ahmad FA, et al. Anti-remodeling and anti-fibrotic effects of the neuregulin-1beta glial growth factor 2 in a large animal model of heart failure. Journal of the American Heart Association. 2014; 3(5):e000773. doi:10.1161/JAHA.113.000773 PMID: 25341890; PubMed Central PMCID: PMC4323814.
11. D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, et al. ERBB2triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat Cell Biol. 2015; 17(5):627-38. doi:10.1038/ncb3149 PMID: 25848746.
12. Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011; 13(1):83-92. doi:10.1093/eurjhf/hfq152 PMID: 20810473.
13. Polizzotti BD, Ganapathy B, Walsh S, Choudhury S, Ammanamanchi N, Bennett DG, et al. Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window. Sci Transl Med. 2015; 7(281):281ra45. doi:10.1126/scitranslmed.aaa5171 PMID: 25834111.
14. Parodi EM, Kuhn B. Signalling between microvascular endothelium and cardiomyocytes through neuregulin. Cardiovascular research. 2014; 102(2):194-204. Epub 2014/01/31. doi:10.1093/cvr/cvu021 PMID: 24477642; PubMed Central PMCID: PMC3989448.
15. Wadugu B, Kuhn B. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol. 2012; 302(11):H2139-47. Epub 2012/03/20. doi:10.1152/ajpheart.00063.2012 PMID: 22427524.
16. Liu X, Hwang H, Cao L, Buckland M, Cunningham A, Chen J, et al. Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(22):13024-9. PMID: 9789034; PubMed Central PMCID: PMC23694.
17. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. CurrOpin Cell Biol. 2007; 19(2):124-34. PMID: 17314037.
18. Jay SM, Murthy AC, Hawkins JF, Wortzel JR, Steinhauser ML, Alvarez LM, et al. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation. 2013; 128(2):152-61. Epub 2013/06/13. doi:10.1161/CIRCULATIONAHA.113.002203 PMID: 23757312; PubMed Central PMCID: PMC3753575.
19. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995; 378(6555):390-4. PMID: 7477376.
20. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378(6555):394-8. PMID: 7477377.
21. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995; 378 (6555):386-90. PMID: 7477375.
22. Erickson SL, O'Shea KS, Ghaboosi N, Loverro L, Frantz G, Bauer M, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development. 1997; 124(24):4999-5011. PMID: 9362461.
23. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998; 273(17):10261-9. PMID: 9553078.
24. Engel FB, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB, et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev. 2005; 19(10):1175-87. PMID: 15870258.
25. Gemberling M, Karra R, Dickson AL, Poss KD. Nrg1 is an injury-induced cardiomyocyte mitogen forthe endogenous heart regeneration program in zebrafish. eLife. 2015;4:e05871. doi:10.7554/eLife.05871 PMID: 25830562; PubMed Central PMCID: PMC4379493.
26. Liu J, Bressan M, Hassel D, Huisken J, Staudt D, Kikuchi K, et al. A dual role for ErbB2 signaling in cardiac trabeculation. Development. 2010; 137(22):3867-75. Epub 2010/10/28. doi:10.1242/dev.053736 PMID: 20978078; PubMed Central PMCID: PMC3049280.
27. Hertig CM, Kubalak SW, Wang Y, Chien KR. Synergistic roles of neuregulin-1 and insulin-like growth factor-I in activation of the phosphatidylinositol 3-kinase pathway and cardiac chamber morphogenesis. J Biol Chem. 1999; 274(52):37362-9. PMID: 10601306.
28. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7(7):505-16. Epub 2006/07/11. doi:10.1038/nrm1962 PMID: 16829981.
29. Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. The New England journal of medicine. 2012; 367(22):2150-3. Epub 2012/11/30. doi:10.1056/NEJMcibr1203156 PMID: 23190227.
30. Yutzey KE. Regenerative biology: Neuregulin 1 makes heart muscle. Nature. 2015; 520(7548):445-6. doi:10.1038/520445a PMID: 25903623.
31. Santoro F, Sahara M. A specified therapeutic window for neuregulin-1 to regenerate neonatal heart muscle. Annals of Translational Medicine. 2015; 3(17).
32. Polizzotti BD, Ganapathy B, Haubner BJ, Penninger JM, Kuhn B. Acryoinjury model in neonatal mice for cardiac translational and regeneration research. Nat Protoc. 2016; 11(3):542-52. doi:10.1038/nprot.2016.031 PMID: 26890681.
33. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. PMID: 18546601.
34. Jansen SA, Conzen SD, Fan X, Krausz T, Zamora M, Foxley S, et al. Detection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation. Physics in medicine and biology. 2008; 53(19):5481-93. doi:10.1088/0031-9155/53/19/014 PMID: 18780960; PubMed Central PMCID: PMC4251813.
35. Jansen SA, Conzen SD, Fan X, Markiewicz E, Krausz T, Newstead GM, et al. In vivo MRI of early stage mammary cancers and the normal mouse mammary gland. NMR in biomedicine. 2011; 24(7):880-7. doi:10.1002/nbm.1643 PMID: 21264977; PubMed Central PMCID: PMC4251780.
36. Moondra V, Sarma S, Buxton T, Safa R, Cote G, Storer T, et al. Serum Neuregulin-1beta as a Bio-marker of Cardiovascular Fitness. Open Biomark J. 2009; 2:1-5. doi:10.2174/1875318300902010001 PMID: 20634924; PubMed Central PMCID: PMCPMC2903891.
37. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation. 2009; 120(4):310-7. Epub 2009/07/15. CIRCULATIONAHA. 109.856310 [pii] doi: 10.1161/CIRCULATIONAHA.109.856310 PMID: 19597049; PubMed Central PMCID: PMC2741393.
38. Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 2007; 1773(8):1161-76. doi:10.1016/j.bbamcr.2007.01.002 PMID: 17306385; PubMed Central PMCID: PMCPMC2758354.
39. Rosler TW, Depboylu C, Arias-Carrion O, Wozny W, Carlsson T, Hollerhage M, et al. Biodistribution and brain permeability of the extracellular domain of neuregulin-1-beta1. Neuropharmacology. 2011; 61(8):1413-8. doi:10.1016/j.neuropharm.2011.08.033 PMID: 21903113.
40. Kazmi SJ, Byer SJ, Eckert JM, Turk AN, Huijbregts RPH, Brossier NM, et al. Transgenic Mice Overex-pressing Neuregulin-1 Model Neurofibroma-Malignant Peripheral Nerve Sheath Tumor Progression and Implicate Specific Chromosomal Copy Number Variations in Tumorigenesis. Am J Pathol. 182(3):646-67. doi: 10.1016/j.ajpath.2012.11.017 PMID: 23321323
41. Oral O, Uchida I, Eto K, Nakayama Y, Nishimura O, Hirao Y, et al. Promotion of spermatogonial proliferation by neuregulin 1 in newt(Cynops pyrrhogaster) testis. Mech Dev. 2008; 125(9-10):906-17. doi:10.1016/j.mod.2008.06.004 PMID: 18586089.
42. Jin Y, Uchida I, Eto K, Kitano T, Abe S. Size-selective junctional barrier and Ca(2+)-independent cell adhesion in the testis of Cynops pyrrhogaster: expression and function of occludin. Mol Reprod Dev. 2008; 75(1):202-16. doi:10.1002/mrd.20662 PMID: 17342736.